PLAB Guideline Update 2023: Diabetes & BP | MedRevisions

What changed

• At the time of publication (November 2023), NICE had updated the positioning of SGLT2 inhibitors and GLP-1 receptor agonists within the type 2 diabetes management ladder.
• Hypertension thresholds and first-line treatment choices were refined based on age, ethnicity, and co-morbidity profiles (NICE NG136).
• Monitoring intervals and target ranges were adjusted across both conditions.

Why it matters for your score

• This article is preserved as a record of the 2023 editorial update. NICE guidance on both conditions has continued to evolve since, and the specific drug-ladder positions noted below may have been refined further.
• For your revision, trust the current in-app note on each condition (look for the 'last reviewed' date) rather than the dated bullets in this article.

Practical checklist

• Open the current expert note for type 2 diabetes in-app and confirm the 'last reviewed' date is within the last few months.
• Do the same for the current hypertension note — our team revises it whenever NICE NG136 updates.
• If you find a discrepancy between this historical article and a current note, trust the note and flag the article for review.